Germany consults on new drug pricing mechanism
This article was originally published in Scrip
Germany's IQWiG, the Institute for Quality and Efficiency in Healthcare, now wants feedback on the results of a study of antidepressants trialling a pricing mechanism, the so called "efficiency frontier method", which could end up being used to determine drug prices after AMNOG pricing disagreements. According to the study, the mechanism has shown that prices of bupropion should be €2.93 rather than the current €104.88, IQWiG told Scrip.
You may also be interested in...
Advicenne withdrew its orphan drug designation application for Sibnayal over concerns that a key study was not designed to compare the product to standard of care.
Biogen has described as “exciting” a first-of-a-kind interim data review that has led to expanded recommendations for the company’s spinal muscular atrophy drug Spinraza.
Artificial intelligence can facilitate outcomes agreements and help companies make their value proposition to health technology assessment bodies.